Loading
Acomhal Research
Acomhal Research is a Virginia company developing a peptide drug aimed at the treatment-resistant cells that let cancers such as glioblastoma grow back after treatment.
Also called: Acomhal Research, Inc.
Overview
Acomhal Research, Inc. develops a patented mimetic peptide derived from connexin 43 (Cx43) as an add-on therapy against chemotherapy-resistant cancer cells, with programmes listed in glioblastoma, breast, colon, pancreatic and lung cancer and melanoma. The company reports that the peptide eliminated chemotherapy-resistant glioblastoma cells, including glioma stem cells, in laboratory and animal studies. A 2026 National Cancer Institute STTR award funds alphavirus vector-mediated expression of the Cx43 mimetic peptide, named JM2 in the award abstract, for glioblastoma.
Headquarters
Roanoke, VA, US
Scorecard
All companies#752of 1706 companies, score 2
- modalities +2
0 approved, 0 in phase 3, 0 earlier, 0 targets, 0 registry studies. Formula on the scorecards page.
Funding
All startupsStartup
Investors not recorded; see the round sources.
Rounds on record
| Round | Year | Amount | Source |
|---|---|---|---|
| Grant · NCI STTR (R41) award 1R41CA306619-01A1: Alphavirus vector-mediated expression of a connexin43 mimetic peptide in glioblastoma therapy | 2026 | $400K | reporter.nih.gov |
Amounts only where the cited source states them. Rounds without a public source are not listed.
Type
Stage
Startup
Website
Products
1PreclinicalMimetic peptide
JM2 is an experimental peptide from Acomhal Research aimed at the stem-like cells that let glioblastoma grow back. It has not yet been tested in people.
Notes
- Company website (home and glioblastoma pages) and the NIH RePORTER record read on 4 November 2026. The website does not name its peptide; the name JM2 is from the award abstract.
Connected
3Sources
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
acomhal.com · 2
nih.gov · 1
A source that has moved or gone is reported by the weekly link check. /audit/